Literature DB >> 8094789

Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline.

J L Montastruc, B Chamontin, J M Senard, M A Tran, O Rascol, M E Llau, A Rascol.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094789     DOI: 10.1016/0140-6736(93)90313-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

Review 1.  Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.

Authors:  G Eisenhofer; T T Huynh; M Hiroi; K Pacak
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

2.  Pitfalls in the diagnosis of phaeochromocytoma.

Authors:  L Zendron; J Fehrenbach; C Taverna; M Krause
Journal:  BMJ       Date:  2004-03-13

Review 3.  New directions in the drug treatment of Parkinson's disease.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 5.  Drug-induced hypertension. Recognition and management in older patients.

Authors:  P W de Leeuw
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 6.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 7.  Monoamine oxidase inhibitors. An update on drug interactions.

Authors:  M G Livingston; H M Livingston
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

8.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 9.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 10.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.